Tag
2 #monoclonal antibody
Clinical
2026-08-01
Antibody ALMB-0166 Calms Overactive Astrocytes — Safety and Early Signals from a First-in-Human Trial in Spinal Cord Injury
ALMB-0166, the first Cx43-hemichannel antibody, given as a single dose to 24 SCI patients: adverse events matched placebo, 1200/2400mg improved scores, two reached AIS E. A small, exploratory result.
解説を読む →
Clinical
2026-07-27
Can the Brain Reclaim a Bladder That Won’t Move After Spinal Cord Injury? — What the Anti-RGMa Antibody Elezanumab Showed in Rats
Neurogenic bladder afflicts more than 80% of people with spinal cord injury. A careful reading of a preclinical study reporting that the anti-RGMa antibody elezanumab improved voiding function and neuroplasticity in rats. Efficacy in humans has not yet been shown.
解説を読む →